PDE5A and cancer: For Stage II cancers, PDE5 inhibitor exposure was also associated with significantly improved 3- and 5-year OS compared with controls (1-year OS not measurable; 3‐year OS 97.0% vs 90.5%, p<0.001; 5‐year OS 93.3% vs 85.5%, p<0.001; HR, 0.41 [95% CI, 0.28–0.59]; Figure 1).